Australia's Clinuvel Pharmaceuticals slips after Jefferies cuts target price on trial setback

Clinuvel Pharmaceuticals

27/04/2026 03:58

** Shares of Clinuvel Pharmaceuticals CUV.AX fall as much as 1.2% to A$8.93

** Jefferies cuts biopharma co's PT to A$39.2 from A$40.5, maintains "buy" rating

** Brokerage flags regulatory snags and delays in clinical trials for vitilgo, an autoimmune disease that affects the skin; phase 3 study of treatment to begin in 2HCY26

** Expects revenue from treatment in 2HFY29 from FY28 predicted earlier, cuts FY28 EPS estimate by about 45%

** All seven analysts rate stock "buy" or higher; median PT is A$23.29 - LSEG-compiled data

** YTD, stock down 27.8%

(Reporting by Aamir Sheik Khalid in Bengaluru)

((Aamir.SheikKhalid@thomsonreuters.com))